Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexchlorpheniramine
Drug ID BADD_D00626
Description Dexchlorpheniramine is a potent S-enantiomer of chlorpheniramine. The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions. It is an antihistamine drug with anticholinergic (drying) and sedative actions. It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells.
Indications and Usage Not Available
Marketing Status experimental; investigational
ATC Code R06AB02
DrugBank ID DB13679
KEGG ID D07803
MeSH ID C018904
PubChem ID 33036
TTD Drug ID D05ZGQ
NDC Product Code Not Available
UNII 3Q9Q0B929N
Synonyms dexchlorpheniramine | dexclorfeniramine | dexchlorpheniramine, (+-)-isomer | dexchlorpheniramine, (R)-isomer | dexchlorpheniramine, monohydrochloride, (S)-isomer | Dexclor | Polaramine | Polaramin | dexchlorpheniramine monohydrochloride | Polaronil | dexchlorpheniramine maleate | dextrochlorpheniramine maleate | dexchlorpheniramine maleate (1:1), (+-)-isomer | dexchlorpheniramine maleate (1:1), (R)-isomer | dexchlorpheniramine maleate (1:1), (S)-isomer | dexchlorpheniramine sodium maleate (1:1) | Polargen TD
Chemical Information
Molecular Formula C16H19ClN2
CAS Registry Number 25523-97-1
SMILES CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.001--Not Available
Asthenia08.01.01.001--Not Available
Chest discomfort02.02.02.009; 22.12.02.002; 08.01.08.019--Not Available
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Conversion disorder19.24.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Dyspepsia07.01.02.001--
Euphoric mood19.04.02.006--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Haemolytic anaemia01.06.03.002--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.004--
Insomnia19.02.01.002; 17.15.03.002--
Irritability19.04.02.013; 08.01.03.011--
Labyrinthitis11.01.05.002; 04.04.03.001--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Neuritis17.09.03.001--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Seizure17.12.03.001--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene